A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

Amid ongoing controversy, U.S. Sen. Maggie Hassan (D-N.H.) is investigating GSK for replacing a popular asthma inhaler with a ...

Emerging as the leader in ultra-rare diseases treatments, Alexion has been a huge success story, bringing breakthroughs to disabling and fatal conditions. But this success brings pressure from ...

(Pharmalot) Reference links: FDA news release. ClaireMorris. 22 April, 2013. Bookmark this. Editor's Picks. Gilead's twice-yearly PrEP drug is cleared by FDA .